Try our beta test site
23 studies found for:    ablynx
Show Display Options
Rank Status Study
1 Recruiting Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection
Condition: Respiratory Syncytial Virus Lower Respiratory Tract Infection
Interventions: Biological: ALX-0171 Dose 1;   Biological: ALX-0171 Dose 2;   Biological: ALX-0171 Dose 3;   Other: Placebo
2 Recruiting An Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention: Biological: ALX-0061
3 Recruiting Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Condition: Acquired Thrombotic Thrombocytopenic Purpura
Intervention: Biological: caplacizumab
4 Recruiting Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Condition: Acquired Thrombotic Thrombocytopenic Purpura
Interventions: Biological: caplacizumab;   Biological: placebo
5 Recruiting A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Biological: ALX-0061;   Biological: Placebo
6 Completed A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Biological: ALX-0061;   Other: Placebo
7 Completed A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171
Condition: Respiratory Syncytial Virus Infection
Interventions: Biological: ALX-0171;   Other: Placebo
8 Completed Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura
Interventions: Biological: anti-vWF Nanobody;   Biological: Placebo;   Other: Plasma exchange
9 Completed A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Biological: ALX-0061;   Biological: Placebo;   Biological: Tocilizumab
10 Completed Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.
Condition: Healthy Volunteers
Intervention: Biological: Caplacizumab
11 Completed ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers
Condition: RSV Infection
Interventions: Biological: ALX-0171;   Biological: Placebo
12 Completed Study Comparing The Tolerability Of Three Excipient Formulations Administered Subcutaneously To Healthy Subjects
Condition: Healthy
Intervention: Other: Formulation buffers
13 Completed A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects
Condition: Healthy
Intervention: Drug: PF-05230905
14 Completed Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Biological: ATN-103 10 mg q4wks;   Biological: ATN-103 30 mg q4wks;   Biological: ATN-103 80 mg q4wks;   Biological: ATN-103 10 mg q8wks;   Biological: ATN-103 80 mg q8wks
15 Completed Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis
Condition: Active Rheumatoid Arthritis
Interventions: Drug: ATN-103;   Drug: Placebo;   Drug: Methotrexate
16 Completed ALX-0061 Phase I Bioavailability Study in Healthy Volunteers
Condition: Rheumatoid Arthritis
Intervention: Biological: ALX-0061
17 Completed ALX-0171 Safety Study in Adults With Hyperresponsive Airways
Condition: Respiratory Syncytial Virus Infection
Intervention: Biological: ALX-0171
18 Completed ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers
Conditions: Healthy;   RSV Infection
Intervention: Biological: ALX-0171
19 Terminated First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4
Condition: Healthy Volunteers
Interventions: Biological: ALX-0651;   Biological: Placebo
20 Completed Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Interventions: Biological: ALX-0061;   Biological: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.